Renaissance Technologies's UTHR Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 2.2M shares of United Therapeutics Corporation (UTHR) worth $911.11 M, representing 1.20% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in UTHR, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2019, adding 799.2K shares. Largest reduction occurred in Q1 2021, reducing 399.7K shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +590,379 | Add 0.00% | 590,378 | $65.82 |
| Q3 2013 | -149,600 | Reduce 25.34% | 440,778 | $78.85 |
| Q4 2013 | -216,500 | Reduce 49.12% | 224,278 | $113.08 |
| Q1 2014 | +63,662 | Add 28.39% | 287,940 | $94.03 |
| Q2 2014 | -35,462 | Reduce 12.32% | 252,478 | $88.49 |
| Q3 2014 | -250,100 | Reduce 99.06% | 2,378 | $128.68 |
| Q4 2014 | +182,860 | Add 7689.66% | 185,238 | $129.49 |
| Q1 2015 | +261,262 | Add 141.04% | 446,500 | $172.43 |
| Q2 2015 | +365,078 | Add 81.76% | 811,578 | $173.95 |
| Q3 2015 | +55,200 | Add 6.80% | 866,778 | $131.24 |
| Q4 2015 | -314,700 | Reduce 36.31% | 552,078 | $156.61 |
| Q1 2016 | -77,500 | Reduce 14.04% | 474,578 | $111.43 |
| Q2 2016 | -70,278 | Reduce 14.81% | 404,300 | $105.92 |
| Q3 2016 | -14,200 | Reduce 3.51% | 390,100 | $118.08 |
| Q4 2016 | +31,100 | Add 7.97% | 421,200 | $143.43 |
| Q1 2017 | +85,000 | Add 20.18% | 506,200 | $135.38 |
| Q2 2017 | +331,400 | Add 65.47% | 837,600 | $129.73 |
| Q3 2017 | +435,400 | Add 51.98% | 1.27 M | $117.19 |
| Q4 2017 | +189,378 | Add 14.88% | 1.46 M | $147.95 |
| Q1 2018 | +71,500 | Add 4.89% | 1.53 M | $112.36 |
| Q2 2018 | +22,322 | Add 1.46% | 1.56 M | $113.15 |
| Q3 2018 | +387,878 | Add 24.92% | 1.94 M | $127.88 |
| Q4 2018 | +252,700 | Add 13.00% | 2.2 M | $108.90 |
| Q1 2019 | +45,000 | Add 2.05% | 2.24 M | $117.37 |
| Q2 2019 | +799,200 | Add 35.65% | 3.04 M | $78.06 |
| Q3 2019 | +171,300 | Add 5.63% | 3.21 M | $79.75 |
| Q4 2019 | +332,155 | Add 10.34% | 3.54 M | $88.08 |
| Q1 2020 | +45,790 | Add 1.29% | 3.59 M | $94.83 |
| Q2 2020 | +136,595 | Add 3.80% | 3.73 M | $121.00 |
| Q3 2020 | -17,800 | Reduce 0.48% | 3.71 M | $101.00 |
| Q4 2020 | -101,727 | Reduce 2.74% | 3.61 M | $151.79 |
| Q1 2021 | -399,700 | Reduce 11.08% | 3.21 M | $167.27 |
| Q2 2021 | -97,400 | Reduce 3.04% | 3.11 M | $179.41 |
| Q3 2021 | -81,600 | Reduce 2.62% | 3.03 M | $184.58 |
| Q4 2021 | -111,400 | Reduce 3.68% | 2.92 M | $216.08 |
| Q1 2022 | -151,978 | Reduce 5.21% | 2.77 M | $179.41 |
| Q2 2022 | +28,378 | Add 1.03% | 2.79 M | $235.64 |
| Q3 2022 | -243,377 | Reduce 8.71% | 2.55 M | $209.38 |
| Q4 2022 | -205,722 | Reduce 8.07% | 2.34 M | $0.28 |
| Q1 2023 | -117,078 | Reduce 4.99% | 2.23 M | $0.22 |
| Q2 2023 | -40,200 | Reduce 1.80% | 2.19 M | $0.22 |
| Q3 2023 | +63,294 | Add 2.89% | 2.25 M | $225.87 |
| Q4 2023 | -80,294 | Reduce 3.57% | 2.17 M | $219.89 |
| Q1 2024 | -18,500 | Reduce 0.85% | 2.15 M | $229.72 |
| Q2 2024 | +22,978 | Add 1.07% | 2.17 M | $318.55 |
| Q3 2024 | -19,300 | Reduce 0.89% | 2.16 M | $358.35 |
| Q4 2024 | -66,000 | Reduce 3.06% | 2.09 M | $352.84 |
| Q1 2025 | +17,600 | Add 0.84% | 2.11 M | $308.27 |
| Q2 2025 | +12,100 | Add 0.57% | 2.12 M | $287.35 |
| Q3 2025 | +54,300 | Add 2.56% | 2.17 M | $419.21 |
Renaissance Technologies's United Therapeutics Corporation Investment FAQs
Renaissance Technologies first purchased United Therapeutics Corporation (UTHR) in Q2 2013, acquiring 590,378 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held United Therapeutics Corporation (UTHR) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to United Therapeutics Corporation (UTHR) was in Q2 2019, adding 3,040,978 shares worth $237.38 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 2,173,392 shares of United Therapeutics Corporation (UTHR), valued at approximately $911.11 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 1.20% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in United Therapeutics Corporation (UTHR) was 3,726,818 shares, as reported at the end of Q2 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.